Form 4: Lonnel Coats Acquires Stock Options in Verve Therapeutics

Director Lonnel Coats acquired stock options in Verve Therapeutics, Inc. on June 26, 2024, under the company's 2021 Stock Incentive Plan.

Summary

• Lonnel Coats, a director of Verve Therapeutics, Inc., acquired stock options to purchase 136,139 shares of common stock on June 26, 2024.
• The options were granted under the company's 2021 Stock Incentive Plan as part of the director compensation program.
• The exercise price of the options is $5.02 per share.
• The options vest upon the earlier of the one-year anniversary of the grant date (June 26, 2024) or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The expiration date of the options is June 25, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) and doesn't indicate any significant positive or negative developments for the company. The sentiment is neutral to slightly positive as it incentivizes the director.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

Stock options are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, are common practice among publicly traded biotechnology companies like Verve Therapeutics.
• Comparable companies such as CRISPR Therapeutics and Beam Therapeutics also utilize stock options as part of their director compensation programs to attract and retain qualified board members.
• The vesting schedules and exercise prices are generally aligned with industry standards to incentivize long-term value creation and align director interests with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.

Key Dates